Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396
Key claim: FDA cleared the IND for PRT12396, a mutant-selective allosteric JAK2V617F inhibitor that targets the JH2 deep pocket, enabling clinical development in MPNs.
Abstract
Prelude Therapeutics announced FDA clearance of IND for PRT12396, a mutant-selective JAK2V617F inhibitor for MPNs. The JAK2 V617F mutation impacts approximately 95% of PV patients, 60% of ET patients, and 55% of MF patients. This allosteric inhibitor targets the JAK2 JH2 deep pocket where the V617F mutation resides.
Why this matters
PRT12396 is the first mutant-selective allosteric JAK2V617F inhibitor to clear FDA IND, joining the next-generation JAK2-targeted pipeline alongside the type II JAK2 inhibitor AJ1-11095. Because JAK2V617F drives ~95% of PV, ~50–60% of ET, and ~50–60% of PMF, a JH2-pocket-selective agent that spares wild-type JAK2 signaling is directly relevant to subtype-specific natural history — particularly the lower-burden ET setting where pan-JAK therapeutic windows are narrow, and the JAK2V617F-mutated PMF subpopulation where durable disease modification remains an unmet need. The IND clearance is incremental (the Phase 1 protocol was already logged) but confirms the class has crossed the preclinical-to-clinical threshold.